Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).

8 Sep 2025

Qureight analyze of Insilico Medicine's Phase IIa rentosertib data support preliminary efficacy results and future trial expansion

Qureight, a techbio company accelerating drug development using its proprietary deep-learning image biomarkers and clinical data analytics platform, today announced the first results from a collaboration with Insilico Medicine ("Insilico"), a clinical-stage biotechnology company driven by generative AI, focused on rentosertib (ISM001-055), a novel TNIK inhibitor discovered using Insilico's generative AI approach, in development for the treatment of IPF.

16 Jul 2025

Dual targeting of lipid kinases offers hope against emerging viruses

Lipid kinases are enzymes that play a critical role in both cell signalling and membrane trafficking by phosphorylating lipid molecules in the body.

14 Jul 2025

Aspartame triggers genetic changes tied to glioblastoma severity

Study shows aspartame affects gut microbiome and gene expression in glioblastoma, highlighting potential links to cancer progression and treatment strategies.

8 Jul 2025

Targeting a key enzyme could reverse early Parkinson's effects

Putting the brakes on an enzyme might rescue neurons that are dying due to a type of Parkinson's disease that's caused by a single genetic mutation, according to a new Stanford Medicine-led study conducted in mice.

2 Jul 2025

MD Anderson researchers present promising clinical trial results at AACR 2025

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025.

26 Apr 2025

Genetic fusion drives unexpectedly fast growth in chronic myeloid leukemia

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in life and how fast it grows.

9 Apr 2025

Tolebrutinib shows promise for treating non-relapsing secondary progressive multiple sclerosis

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood disorders, demonstrated a 31% delay in the onset of six-month confirmed disability progression (CDP) in patients with non-relapsing secondary progressive multiple sclerosis (SPMS).

8 Apr 2025

Blood cancer patients should continue BTKi therapy during COVID-19 vaccination

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study suggests.

2 Apr 2025

Scientists discover key genes for regenerating cells in the ear and eye

The same genes could hold the key to regenerating cells in the ear and eye, according to a new mouse study from the USC Stem Cell laboratory of Ksenia Gnedeva, PhD, published in the Proceedings of the National Academy of Sciences (PNAS).

1 Apr 2025

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

26 Mar 2025

Circadian rhythms play a crucial role of in regulating tumor progression

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external light-dark cycles.

21 Mar 2025

Advancements in molecular diagnostics for hematopoietic and lymphocytic neoplasms

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

27 Feb 2025

Innovative combination of treatments effectively kills acute myeloid leukemia cells

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer.

27 Feb 2025

Vimseltinib gains FDA approval for treating tenosynovial giant cell tumor

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.

20 Feb 2025

Study uncovers two inhibitors to halt metaplastic breast cancer progression

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

3 Feb 2025

New approach to treating ependymoma with leukemia drug

Rakesh Jain PhD, Director of the E.L. Steele Laboratories for Tumor Biology at Massachusetts General Hospital and A. Werk Cook Professor of Radiation Oncology at Harvard Medical School, is senior author of a new study in PNAS, Targeting EPHB2/ABL1 Restores Anti-Tumor Immunity in Preclinical Models of Ependymoma.

23 Jan 2025

AGA releases updated guidelines on hepatitis B reactivation in patients on immunosuppressive drugs

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation (HBVr) in patients on immunosuppressive drugs.

23 Jan 2025

Gut microbes revealed as hidden drivers of aging and cellular decline

Gut microbiota-derived phenylacetylglutamine accelerates aging by driving cellular senescence through mitochondrial dysfunction and DNA damage, offering insights into therapeutic interventions for age-related decline.

14 Jan 2025

New drug cocktail enhances CAR-T cells for cancer treatment

Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts (chimeric antigen receptor-T cells) to fight cancer.

13 Jan 2025